--- name: managing-clinical-trial-eligibility language: en description: Screens patients against clinical trial inclusion/exclusion criteria with documentation. Use when screening trial candidates, checking eligibility criteria, or documenting trial enrollment decisions. tags: - management - oncology - clinical - patient-care metadata: author: casemark practice_areas: - Medical Oncology - Hematology-Oncology - Radiation Oncology document_types: - Management Report skill_modes: - Management - Coordination --- # Managing Clinical Trial Eligibility Screens patients against clinical trial inclusion/exclusion criteria with documentation. ## Why This Skill Exists Clinical trials are the pathway to novel therapies and improved outcomes, yet only 3–8% of adult cancer patients enroll in clinical trials. The leading barrier is not patient willingness but failure to systematically screen patients against available trial criteria. Incomplete eligibility screening results in screen failures (wasting patient and institutional resources), missed enrollment opportunities, and protocol deviations that jeopardize trial integrity. FDA regulations (21 CFR Parts 50, 56, 312) and ICH-GCP E6(R2) guidelines mandate documented eligibility verification before enrollment. NCI Clinical Trials Reporting Program (CTRP) requires accurate screening and enrollment documentation. CoC Standard 5.6 requires that cancer programs accrue patients to clinical research. Incorrect eligibility determination can result in patient harm, protocol violations, FDA audit findings, and loss of institutional trial participation privileges. --- ## Checkpoint A: Pre-Draft Intake (Mandatory) 1. What is the patient's confirmed diagnosis with histology, stage, and biomarker status? (Default: [VERIFY]) 2. What line of therapy has the patient reached? (Default: specify all prior regimens and responses) 3. What is the patient's current ECOG performance status? (Default: most recent assessment) 4. What are the available clinical trials for this disease and setting? (Default: search ClinicalTrials.gov and institutional trial portfolio) 5. What are the patient's current organ function labs (renal, hepatic, cardiac, hematologic)? (Default: labs within 14 days) 6. Has the patient expressed willingness to participate in a clinical trial? (Default: not yet assessed) 7. Are there logistic barriers (distance, insurance, caregiver support)? (Default: assess) 8. Does the patient have active autoimmune disease, uncontrolled infection, or organ transplant history? (Default: review medical history) ### Documents to Request - Full protocol inclusion/exclusion criteria for each candidate trial - Complete medical history including comorbidities - All prior cancer treatment records with dates, agents, doses, responses, and toxicities - Current labs: CBC with differential, CMP, LFTs, LDH, TSH, urinalysis - Cardiac function assessment (LVEF by echo or MUGA if required by protocol) - Current medication list (to screen for prohibited concomitant medications) - Recent imaging (within protocol-specified window, typically 28 days) - Molecular and biomarker test results required by the protocol --- ## Step 1: Identify Candidate Trials Search strategy: 1. **ClinicalTrials.gov** — filter by disease, stage, biomarkers, line of therapy, and recruiting status 2. **Institutional trial portfolio** — check active protocols at the treating institution 3. **NCI Cancer Information Service** — for NCI-sponsored cooperative group trials 4. **Pharmaceutical sponsor portals** — for industry-sponsored trials with sites in the patient's region 5. **Molecular matching platforms** — NCI-MATCH, TAPUR, and tumor-agnostic basket trials for actionable mutations For each candidate trial, document: NCT number, phase, sponsor, primary endpoint, treatment arm(s), and required biomarker status. --- ## Step 2: Screen Against Inclusion Criteria For each candidate trial, verify every inclusion criterion: **Common inclusion criteria categories:** | Category | Typical Requirements | Documentation Source | |----------|---------------------|---------------------| | Diagnosis | Histologically confirmed specific cancer type | Pathology report | | Stage | Specific stage or metastatic disease | Staging workup | | Biomarkers | Specific mutation, PD-L1 level, MSI status | Molecular testing | | Prior therapy | Specific number of prior lines or specific agents received | Treatment records | | Performance status | ECOG 0–1 (most trials) or 0–2 | Clinical assessment | | Organ function | Adequate renal (CrCl ≥30–60), hepatic (bilirubin ≤1.5× ULN, AST/ALT ≤2.5–3× ULN), hematologic (ANC ≥1500, platelets ≥100K) | Labs within 14 days | | Measurable disease | Per RECIST 1.1 (≥10mm in longest diameter for non-nodal, ≥15mm short axis for lymph nodes) | Imaging | | Consent capacity | Ability to provide informed consent | Clinical assessment | Mark each criterion: MET / NOT MET / PENDING (with plan to obtain). --- ## Step 3: Screen Against Exclusion Criteria Common exclusion criteria requiring documentation: - **Prior therapy washout:** Most trials require 2–4 weeks since last systemic therapy, 2 weeks since radiation, 4 weeks since major surgery. Verify specific washout periods per protocol. - **Active brain metastases:** Many trials exclude untreated or symptomatic brain metastases. Previously treated, stable brain metastases may be permitted. Document brain MRI date and findings. - **Autoimmune disease:** Particularly relevant for immunotherapy trials. Document specific condition, current treatment, and disease activity. - **Concomitant medications:** Many trials prohibit strong CYP3A4 inhibitors/inducers, systemic corticosteroids above physiologic dose (>10mg prednisone equivalent), or specific drug classes. Screen current medication list against protocol prohibited medications. - **Cardiac function:** Trials may exclude QTc >470ms, LVEF <50%, recent MI or unstable angina within 6 months. Document most recent EKG and LVEF. - **Prior organ transplant:** Typically excluded from immunotherapy trials due to risk of allograft rejection. - **Active infections:** HIV, HBV, HCV status may need documentation. Active infections generally must be resolved before enrollment. Mark each exclusion criterion: NOT PRESENT (eligible) / PRESENT (ineligible) / REQUIRES CLARIFICATION. --- ## Step 4: Document Eligibility Determination For each screened trial, produce a structured eligibility report: 1. **Trial identification:** NCT number, protocol title, PI name, phase 2. **Inclusion criteria checklist:** Each criterion with MET/NOT MET/PENDING 3. **Exclusion criteria checklist:** Each criterion with NOT PRESENT/PRESENT/PENDING 4. **Overall eligibility determination:** ELIGIBLE / POTENTIALLY ELIGIBLE (pending items) / INELIGIBLE 5. **If ineligible:** Specify the disqualifying criterion with supporting documentation 6. **If potentially eligible:** List pending items with timeline to resolve (e.g., "awaiting BRCA results, expected within 10 business days") 7. **Next steps:** Schedule consent discussion, order pending tests, refer to trial site --- ## Step 5: Manage the Screening-to-Enrollment Pathway After identifying eligible trials: 1. Prioritize trials by: therapeutic potential > phase III over phase I for treatment-naive patients > logistic feasibility 2. Coordinate the screening visit timeline — most protocols require labs and imaging within specific windows (14–28 days of enrollment) 3. Ensure informed consent is obtained by qualified personnel per ICH-GCP requirements 4. Complete all protocol-required screening procedures before randomization 5. Document the enrollment decision and communicate to the care team 6. If patient declines trial participation, document the reasons and proceed with standard-of-care treatment --- ## Checkpoint B: Post-Draft Alignment (Mandatory) 1. Has every inclusion and exclusion criterion been individually verified with supporting documentation? 2. Are all labs and imaging within the protocol-specified screening window? 3. Have prohibited concomitant medications been screened and documented? 4. Is the eligibility determination clearly stated with the disqualifying criterion identified if ineligible? 5. Has the screening-to-enrollment timeline been mapped to avoid window expiration? --- ## Quality Audit - [ ] ClinicalTrials.gov search documented with search parameters and date - [ ] NCT number recorded for each screened trial - [ ] Each inclusion criterion individually verified with source documentation - [ ] Each exclusion criterion individually verified with source documentation - [ ] ECOG performance status assessed within protocol-required timeframe - [ ] Organ function labs within protocol-specified screening window - [ ] RECIST 1.1 measurable disease confirmed on imaging within required window - [ ] Concomitant medication list screened against protocol prohibitions - [ ] Brain imaging obtained if required by protocol - [ ] Cardiac function assessed if required by protocol - [ ] Eligibility determination clearly stated (eligible/ineligible/pending) - [ ] Screen failures documented with specific disqualifying criterion - [ ] Enrollment timeline mapped with key milestone dates - [ ] Informed consent process documented per ICH-GCP --- ## Guidelines - Screen every newly diagnosed advanced/metastatic cancer patient for clinical trial eligibility before initiating standard-of-care therapy - Never assume ineligibility without verifying each criterion against the protocol — many patients are incorrectly excluded based on assumptions - Protocol amendments may change eligibility criteria — always verify against the current amendment - Washout periods are calculated from the last dose of the prior agent, not from the last cycle start date - ECOG performance status for trial eligibility must be assessed by a physician, not extrapolated from nursing notes - Molecular testing turnaround time must be factored into screening timelines — order early to prevent delays - Document why a trial was not pursued, even if the reason is logistic — this supports quality metrics and identifies barriers to accrual - For patients on anticoagulation, verify whether the specific trial permits anticoagulant use — many phase I trials restrict this